From Alphastreet - Earnings Decoded. Market Intelligence Delivered · AlphaStreet Newsdesk · · 50s
United Therapeutics Drops 5.2% Despite BTIG Buy Rating
United Therapeutics shares fell 5.2% Friday as BTIG upgraded to buy with $728 target.
In brief
United Therapeutics shares fell 5.2% Friday as BTIG upgraded to buy with $728 target. United Therapeutics dropped 5.2% Friday despite BTIG's buy rating and $728 price target. Originally reported by Alphastreet - Earnings Decoded. Market Intelligence Delivered.
United Therapeutics Plunges
United Therapeutics Corporation plunged 5.2% on friday despite a bullish call from btig.
BTIG Upgrades to Buy
btig issued a buy rating with a price target of $728 implying significant upside.
Market Reaction
shares closed at $541.71 on heavy volume of 532,201 shares as market cap dropped.
Volume Spike
the 532,201 shares changed hands indicate heightened activity as investors digest the analyst call.
Investor Skepticism
investors may be skeptical of btig's $728 target or weighting other factors more heavily.
What to Watch
investors should monitor stock support at current levels or if selling pressure persists next week.
The takeaway
United Therapeutics dropped 5.2% Friday despite BTIG's buy rating and $728 price target.
